Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
alopecia
Biotech
Nektar claims ph. 2 alopecia success after excluding 4 patients
Rezpeg significantly reduced scalp hair loss severity in an analysis that excluded four patients who ‘should never have been enrolled’ in the trial.
Darren Incorvaia
Dec 16, 2025 5:05pm
Fierce Pharma
Veradermics grows hair loss med hopes on $150M funding wave
Oct 16, 2025 7:30am
Pelage locks in $120M series B for hair growth program
Oct 15, 2025 7:00am
HCW Biologics clings on with $5M lifeline to fund alopecia trial
May 16, 2025 7:00am
Q32 Bio sticks with bempikibart but lets go of staff
Feb 11, 2025 4:47am
Q32's stock plunges in wake of anti-IL-7R antibody's eczema fail
Dec 11, 2024 8:25am